The Woman’s Board Fund for Excellence in Cellular Therapy
Reshaping expectations of what’s possible in the treatment of solid tumor cancers
New cellular therapies harnessing the power of the immune system are already reshaping physicians’ expectations of what’s possible in the treatment of lymphoma, leukemia and other hematologic malignancies. Now RUSH is poised to become one of the nation’s first clinical trial sites for tumor-infiltrating lymphocytes, or TIL therapy — a potential treatment breakthrough for solid tumor cancers showing earliest promise in lung cancer and melanoma. TIL therapy involves collecting a person’s own cancer-fighting cells, re-engineering them in the laboratory to attack tumors more precisely, and massively multiplying their quantity before reinfusing them back into the patient. The culmination of years of research and development, TIL therapies in the pipeline represent our best hope to cure many patients whose cancer is resistant to current treatments.
The Woman’s Board Fund for Excellence in Cellular Therapy will facilitate the work of RUSH physician-scientists introducing these exciting, but highly complex, cellular therapies into patient care. Providing for care coordination, research to further personalize these novel therapies and support for patients undergoing treatment, funds will strengthen RUSH’s current position as a destination program in the Midwest for lung cancer, melanoma and hematologic malignancies — areas where cell therapies are rapidly advancing.